- Report
- August 2023
- 51 Pages
United Kingdom
From €537EUR$600USD£459GBP
- Report
- August 2023
- 51 Pages
Turkey
From €537EUR$600USD£459GBP
- Report
- August 2023
- 51 Pages
Canada
From €537EUR$600USD£459GBP
- Report
- June 2021
- 50 Pages
China
From €2326EUR$2,600USD£1,989GBP
- Report
- May 2021
- 50 Pages
China
From €2326EUR$2,600USD£1,989GBP
- Report
- July 2022
- 100 Pages
Global
From €3132EUR$3,500USD£2,678GBP
The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more